AXSM
Axsome Therapeutics Inc
193.50$
-4.8%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.5% | 99.9% | 99.4% | 99.3% | 98.9% | 99.9% | 98.9% | 98.6% | 74.1% | 85.7% | 85.3% | 85.4% | |
| 94.0% | 97.9% | 95.8% | 95.7% | 90.8% | 99.7% | 98.8% | 98.5% | 60.6% | 65.7% | 55.5% | 46.8% | |
| 94.0% | 97.9% | 95.8% | 95.7% | 90.8% | 99.7% | 98.8% | 98.5% | 60.6% | 65.7% | 55.5% | 46.8% | |
| – | – | – | – | – | – | – | 0.0% | 11.4% | 16.1% | 25.0% | 32.5% | |
| – | – | 0.0% | 0.0% | – | – | – | 0.0% | 1.3% | 2.6% | 2.8% | 4.1% | |
| – | 0.0% | 0.3% | 0.2% | 0.3% | 0.0% | 0.0% | 0.3% | 0.3% | – | – | – | |
| – | – | 0.0% | 0.0% | – | – | – | 0.0% | 3.1% | 2.0% | 2.1% | 1.7% | |
| – | – | 0.0% | 0.0% | – | – | – | – | 18.0% | 9.1% | 8.2% | 5.9% | |
| 214.9% | 5.4% | 43.5% | 53.0% | 93.9% | 19.0% | 38.9% | 82.2% | 66.9% | 67.5% | 90.0% | 87.2% | |
| 34.9% | 5.4% | 18.8% | 34.2% | 70.4% | 11.1% | 12.6% | 26.3% | 29.1% | 23.6% | 40.5% | 54.9% | |
| 1.5% | – | 0.7% | 9.2% | 21.4% | 1.2% | 0.7% | 0.7% | 0.1% | 0.2% | 0.6% | 10.6% | |
| 27.2% | 3.9% | 10.7% | 9.7% | 24.0% | 5.0% | 7.3% | 15.0% | 11.6% | 6.9% | 12.7% | 9.5% | |
| 159.4% | – | 24.8% | 18.7% | 23.5% | 7.9% | 26.0% | 55.9% | 28.4% | 30.3% | 31.8% | 17.1% | |
| -114.9% | 94.6% | 56.5% | 47.0% | 6.1% | 81.0% | 61.1% | 17.8% | 33.1% | 32.5% | 10.0% | 12.8% | |
| -295.3% | -41.6% | -124.7% | -215.4% | -699.3% | -79.8% | -149.8% | -466.1% | -179.9% | -142.0% | -197.5% | -189.3% | |
| 456.4% | 24.3% | 50.1% | 64.0% | 174.8% | 15.4% | 20.0% | 42.9% | 12.3% | 7.7% | 8.4% | 7.2% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.